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Genetically modified pigs lacking Gala1  3Gal and other immunogenic carbohydrates are considered 
as the most promising, alternative source of various tissues and organs for human transplantation. 
Here, we tested the hypothesis that combining the expression of human al,2-fucosyltransferase 
(hFUT2) and a-galactosidase A (hGLA) genes would allow for the removal of this specific 
carbohydrate in porcine transgenic livers. We investigated the expression profile of human 
al,2-fucosyltransferase and a-galactosidase A proteins and the amount of Gala1  3Gal antigen in the 
liver of single transgenic hFUT2 (n=5), hGLA (n=5), and double transgenic hFUT2xhGLA (n=5) pigs. 
Both human proteins, al,2-fucosyltransferase and a-galactosidase A, were abundantly expressed in 
the liver tissue in respective transgenic lines as was revealed by confocal microscopy and Western 
blotting. The level of Gala1  3Gal epitope evaluated by lectin histochemistry and lectin blotting was 
significantly lower (p<0.05) in all genetically modified livers than that in the control non-transgenic 
porcine livers. Importantly, the double transgenic line expressed a significantly lower (p<0.05), but 
still detectable level of this antigen, compared to both single transgenic pigs, as shown by lectin 
blotting. Histological evaluation of the liver samples stained with haematoxylin and eosin showed no 
morphological evidence of hepatic abnormalities in all transgenic pigs. Our study indicates that the 
simultaneous expression of two protective transgenes hFUT2xhGLA indeed improves the removal of 
the Gala1  3Gal epitope in porcine liver. However, this modification alone is not sufficient enough for 
complete elimination of this antigen from porcine liver tissue.
Key words: Genetically modified pigs, liver, Gala1  3Gal epitope, human a1,2-fucosyltransferase, 
human a-galactosidase A.
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Pigs are considered to be the most suitable, alterna­
tive donors of tissues and organs for human patients 
with acute or chronic organ failure. They share many 
similarities in organ anatomy and physiology and
share an approximately 96% genetic identity with hu­
mans (G a l il i  et a t  1988; COOPER et ah 2002; 
W h y t e  &  P r a t h e r  2011; H r y h o r o w ic z  et al. 
2017). Pigs have good breeding potential and rapid
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growth at a relatively low cost. In addition, porcine 
endogenous retroviruses could be effectively inacti­
vated by CRISPR-Cas9 to prevent their transmission 
to human recipients (NlU et al. 2017).
Unfortunately, the phylogenetic distance between 
pigs and humans entails a complex immune response 
leading to hyperacute rejection as well as acute humo­
ral and cellular rejection o f transplanted pig organs 
(COOPER et al. 2015, 2016; LU et al. 2020). Hyper­
acute rejection is an immediate reaction o f the human 
immune system to the major carbohydrate xenoanti- 
gen Gala I '3Gal. which is abundantly present on the 
surface o f porcine cells, in particular endothelial cells. 
The formation ofthe Galo.1 -SCial epitope is driven by 
the enzyme al,3-galactosyltransferase, encoded by 
the GGTA1 gene (SANDRIN &  M c K f .N7.te 1994). 
GGTA1 is functional in most mammals, including 
pigs, but not in humans and Old World apes (Ga l il i  etal. 
1988; LU etal. 2020). In turn, primates produce natu­
ral xenoreactive antibodies, o f which about 90% rec­
ognise the Galo.1 -3Gal epitope (SANDRIN etal. 1993; 
Me M o r r o w  et al. 1997).
A promising approach to overcome hyperacute rejection 
is generating homozygous al,3-galactosyltransferase 
gene-knockout (GTKO) pigs using zinc finger nucle­
ase (ZFN) technology, transcription activator-like ef­
fector (TALE) nucleases and modifications o f the 
CRISPR/Cas system (LAI etal. 2002; PIERSON2009; 
LADOWSKI et al. 2019). Another strategy to remove 
the Gala. I -3Gal epitope from porcine cells involves 
the combined transgenic expression o f recombinant 
human enzymes al,2-fucosyltransferase (rhal,2-FT) 
and a-galactosidase A (rha-Gal A) (OSMAN et al. 
1997). al,2-fucosyltransferase is encoded by \\FUT2 
and in humans occurs in the cis compartment o f the 
Golgi apparatus. This human enzyme acts earlier than 
porcine endogenous al,3-G T, which is present in the 
trans compartment. This strategy is based on the com­
petition o f these two enzymes acting on the same sub­
strate during oligosaccharide processing in transgenic 
cells. As an oligosaccharide moves through the Golgi 
apparatus from the cis to the trans compartment, it 
is first flicosylated by rhal,2-FT. Hence, this oligo­
saccharide cannot accept the terminal galactose resi­
due in the subsequent reaction catalysed by al,3-G T 
(HARTEL-Sc h e n k  et al. 1991). In turn, the recombi­
nant human a-galactosidase A, encoded by the hGLA 
gene, is responsible for the cleavage o f term inal 
D-galactose residues (LUO et al. 1999). The expres­
sion o f rha.l,2-FT or rha-Gal A alone does not, how­
ever, allow for the complete elimination o f the 
G alal^3G al epitope from pig cells. Thus, it was sug­
gested that the co-expression o f both rhal,2-FT and 
rha-Gal A would be more efficient method for this 
epitope reduction (LUO et al. 1999; ZEYLAND et al. 
2014). Indeed, ZEYLAND etal. (2014) reported forthe 
first time the successfi.il production of double transgenic 
pigs that expressed human a l , 2 -fucosyltransferase 
and a-galactosidase and showed a considerable re­
duction o f the a-Gal antigen level on the surface of 
skin fibroblasts. However, the effect o f transgenic 
modification may vary among different cell types, 
due to their specific glycosylation pattem, and so far 
the impact o f hFUT2 and hGLA transgenes on carbo­
hydrate antigen Gala. I oG al expression has not been 
investigated in any solid organ. Liver is the largest in­
ternal organ in the body and exhibits remarkable re­
generative capacity. The glycosylation o f liver cells 
and secreted proteins play an essential role in regulat­
ing various metabolic and immune functions, per­
formed by parenchymal hepatocytes, sinusoidal 
endothelial cells, hepatic stellate cells, resident 
macrophages (including Kupffer cells), and various 
lymphocytes.
In this context, in the present study we hypothesised 
that the combined actions o f human a 1 ,2 - 
fucosyltransferase and a-galactosidase A enzymes in 
double transgenic \lFUT2x\iGLA pigs are more effi­
cient in eliminating the Gala. I oCial epitope in por­
cine liver than a single expression o f ci ther \\FUT2 or 
h GLA transgenes.
M aterials and M ethods
Animals
All animal procedures were conducted in accor­
dance with the European Directive 2010/63/EU and 
approved by the Second Local Ethics Committee in 
Kraków, Poland (Permission 1181/2015 from 21 of 
May 2015). The liver tissue samples were obtained 
from the Department o f Biotechnology of Reproduc­
tion and Cryopreservation, National Research Insti­
tute o f Animal Production at Balice near Krakow. 
Fresh tissue specimens were taken immediately after 
slaughtering and the opening o f the abdominal cavity 
from 15 transgenic pigs (n=5 for each transgenic vari­
ant) and from 8  non-genetically modified Polish 
Large White pigs. All liver samples were frozen in 
liquid nitrogen for further analyses. The transgenic 
pigs were designed to show the expression o f re­
combinant human al,2-fucosyltransferase (hFUT2), 
a-galactosidase (hGLA) and hFUT2*hGLA (LIPIŃSKI 
et al. 2010; ZEYLAND et al. 2014). The transgenic 
pigs and non-transgenic control pigs were healthy and 
normal in terms o f reproductive capability. They were 
12- to 18-months old and weighed 150-200 kg.
Histological analysis
The frozen liver samples were sectioned at 6  pm in 
Leica CM 1850 UV cryostat (Leica, Biosystems, 
Nussloch, Germany) and collected onto poly-L- 
lysine coated microscopic slides. Cryosections were 
fixed with 4% paraformaldehyde in PBS for 10 min, 
washed in PBS three times for 5 min and then stained 
with haematoxylin (Shandon, ThennoFisher Seien-
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tific, Waltham, MA, USA) for 3 min. Subsequently, 
slides were washed 1 0  min in tap water and were then 
stained with eosin (ThermoFisher Scientific, Waltham, 
MA, USA) for 2 min. After dehydration in a graded 
series of ethanol (70%-100%), followed by two changes 
of xylene, sections were mounted with Consul-Mount™ 
(Shandon™, ThennoFisher Scientific, Waltham, MA, 
USA) and coverslipped. Finally, sections were ana­
lysed using aNikon Optihot-2 bright field microscope 
(Nikon, Tokyo, Japan) equipped with aNikon Digital 
Camera DXM 1200F (Nikon, Tokyo, Japan) and 1 0 x, 
2 0 x, and 40x objective lenses.
Immunofluorescence staining
The porcine liver samples were cryosectioned at 
6  pm and collected onto poly-U-lysine coated micro­
scopic slides. Sections were fixed with a 4% parafor­
maldehyde solution in PBS for 10 min, washed in 
PBS and blocked in 5% Normal Goat Serum/PBST 
(Phosphate buffer saline with 0.1 % v/v Triton X-100, 
Bioshop Inc., Burlington, Canada) for 45 min. Then 
sections were incubated with the primary antibodies 
against: human al,2-fucosyltransferase (Rabbit poly­
clonal antibodies, ab 198712, Abeam) diluted 1:150 in 
PBST; human a-galactosidase (Rabbit polyclonal an­
tibodies, PA5-27349; ThennoFisher Scientific, 
Waltham, MA, USA) diluted 1:200, overnight at +4°C 
in a humidified chamber. In the next step, sections 
were washed several times in PBST and treated with 
appropriate secondary antibodies labelled with Cy3 
(Goat anti Mouse or Goat anti Rabbit, Jackson Im- 
muno Research) diluted 1:600 in PBST, for 1 h at 
room temperature. After final washes, sections were 
mounted in Fluoroshield with DAPI mounting me­
dium (F6057, Sigma-Aldrich, St. Uouis, MO, USA) 
and coverslipped. Fluorescently labelled sections 
were examined by Olympus FV1200 Confocal Mi­
croscope (Olympus, Tokyo, Japan). Relative intensi­
ties o f fluorescence were quantified in each, 
randomly chosen region o f interest (ROI) using Im- 
ageJ version 1.46r software (National Institutes of 
Health, Bethesda, MD, USA) in a greyscale of 
256 levels (GAJDA et al. 2011; ROMEK et al. 2017). 
For each genetically modified and control pig, three 
sections were sampled by 70 ROI.
Double immunofluorescence staining was per­
formed using primary antibodies against human 
al,2-fucosyltransferase (Rabbit polyclonal antibod­
ies, abl98712, Abeam) diluted 1:150 in PBST, and 
antibodies that recognize the Golgi apparatus (58K 
Golgi protein) (Mouse monoclonal antibodies, 
ab27043, Abeam) diluted 1:100 in PBST. The secon­
dary antibodies were Goat anti Rabbit conjugated 
with Alexa Fluor 488 (ThermoFisher Scientific, 
Waltham, MA, USA) diluted 1:300 in PBST, and 
Goat anti Mouse Alexa Fluor 555 labeled (Ther­
moFisher Scientific, Waltham, MA, USA) diluted 
1:600 in PBST.
Lectin histochemistry
The localization and semi quantitative comparison 
of G alal^3G al epitope expression in the liver of 
\iFUT2, hGLA, and hFUT2A\GLA was assessed by 
using a specific lectin from Griffonia simplicifolia 
(GS-IB 4 ) conjugated with Alexa Fluor 647 fluores­
cent dye (132450, Molecular Probes, Invitrogen , 
ThennoFisher Scientific, Waltham, MA, USA). 
Lectin histochemistry was carried out on 6  pm cry- 
ostat sections, which were fixed with 4% paraformal­
dehyde in PBS, washed in PBS and then blocked in 
1% BSA (Bovine Serum Albumin, Bioshop Inc., Bur­
lington, Canada) in PBST for 1 h. Samples were 
washed three times in PBS and treated with lectin 
GS-IB 4  diluted 1:200 in DPBS, at +4°C overnight in 
a dark humidified chamber. After final washes, sec­
tions were mounted in Fluoroshield with DAPI and 
coverslipped. Fluorescently labelled sections were 
examined as described in the paragraph Immunofluo­
rescence staining.
Total protein isolation and Western/Lectin blot
analyses
Total protein was extracted from frozen tissue sam­
ples by using a radioimmunoprecipitation assay lysis 
buffer (RI P A buffer, Thermo Fisher Scientific, 
Waltham, MA, USA) containing 1% of proteinase in­
hibitor cocktail (RIPA+PI; Bioshop Inc., Burlington, 
Canada). Liver samples were cut into small, approxi­
mately 2 mm pieces and homogenized in 300 pi 
RIPA+PL Tissue lysates were centrifuged at 14 000 x g 
for 15 min at +4°C and supernatants collected. Protein 
concentration was determined with microassay DC™ 
Protein Assay (Bio-Rad Laboratories, Hercules, CA, 
USA) using bovine serum albumin as a standard. Pro­
tein samples were stored at minus 80°C for further 
analyses.
Protein samples were diluted in 2 x Laemmli Sample 
Buffer (Bio-Rad Laboratories, Hercules, CA, USA) 
with ß-mercaptoethanol (BME; Sigma-Aldrich, 
St. Louis, MO, USA) and denatured at 100°C for 
5 mm. Then, proteins were separated in SDS-PAGE 
using 5% stacking and 10% resolving gels. Molecular 
weights were estimated with reference to standard 
proteins (Precision Plus Dual Color Protein Standard, 
Bio-Rad Laboratories, Hercules, CA, USA). For im- 
munoblotting, lectin blotting proteins were electro­
transferred onto PVDF membrane (Immobilon, 
Merck, Demistadt, Germany) at a constant amperage 
of 250 mA for 120 min.
For immunoblotting, membranes were blocked for 
1 h in 5% non-fat milk in TBST (Tris buffer saline 
with 0.1% v/v Tween20, Bioshop Inc., Burlington, 
Canada) and after several washes in TBST, incubated 
overnight at +4°C with the following primary anti­
bodies (the same as for immunofluorescent labelling) 
against: human a l , 2 -fucosyltransferase diluted 1 : 1 0 0 0
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in TBST and human a-galactosidase diluted 1:1000 in 
TBST. Then, membranes were washed several times 
in TBST and incubated with appropriate secondary 
antibodies horse radish peroxidase (HRP) conjugated 
(Goat anti-Rabbit or Goat anti-Mouse ThennoFisher 
Scientific, Waltham, MA, US A) at a dilution of 1:6000 
in TBST for 1 h at room temperature. The ß-actin was 
used as a reference protein (ab8224 Abeam, Mouse 
monoclonal antibodies anti-ß-actin) diluted 1 : 2 0 0 0  in 
TBST
For lectin blotting, membranes were blocked for 
30 min in 1% BSA in TBST. After several washes in 
DPBS followed by TBS, membranes were incubated 
overnight at +4°C with lectin GS-IB 4  labelled with 
HRP (L5391, Sigma-Aldrich, St. Louis, MO, USA) 
diluted 1:2000 in DPBS. Finally membranes were 
washed in TBS.
For both immunoblotting and lectin blotting, pro­
tein bands were detected by chemiluminescence us­
ing Clarity™ Western ECL Blotting Substrate 
(Bio-Rad Laboratories, Hercules, CA, USA) and 
visualized with the ChemiDocTM XRS+ Imaging 
System (Bio-Rad Laboratories, Hercules, CA, USA). 
Protein bands were quantified using Image Lab™ 2.0 
Software (Bio-Rad Laboratories, Hercules, CA, USA) 
by measurement o f their relative optical densities. 
Following protein detection in Western blotting, mem­
branes were stripped and reprobed with anti-ß-actin 
antibody, which was used as a reference protein 
(ab8224 Abeam, Mouse monoclonal antibodies 
anti-ß-actin) diluted 1:2000 in TBST.
Statistical analysis
For each genetically modified and non-modified 
group of pigs and for all analyses, three repeats were 
performed. Quantitative data were expressed as the 
mean ± standard error of the mean and examined using 
the Shapiro-Wilk (SW) test for nonnality. Compari­
sons between the appropriate means were performed 
by one-way analysis o f variance (ANOVA), followed 
by the Tukey HSD post hoc test. Statistical signifi­
cance was marked accordingly: *p<0.05, **p<0.01,
***p<0 .0 0 1 .
Results
Histological analysis
Histological analysis oftransgenic and non-transgenic 
porcine livers was performed to examine any possible 
adverse effects o f transgenesis on the morphology of 
porcine liver. Routine staining with haematoxylin and 
eosin showed no visible differences between livers 
from transgenic and non-transgenic pigs in the histo­
logical organisation o f tissue structures such as a por­
tal space, bile ducts, hepatic veins, hepatic arteries, 
and parenchymal cells. Figure 1 shows representative
Fig. 1. Histological analysis of transgenic and non-transgenic 
(control) porcine livers. Representative microphotographs of control 
non-transgenic CTR nTG (a), single transgenic liFUT2, hGLA 
(b, c), and double transgenic hFUT2x\iGLA (d) porcine liver 
cryostat tissue sections. Haematoxylin-eosin staining. The most 
typical elements of the liver structure were marked as follows: 
lv -  liver vein; PZ -  portal venous zone; la -  hepatic artery; bd -  bile 
duct. The analysis showed no histological differences between 
the control and the transgenic samples. Scale bars = 50 pm.
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images of liver tissue sections stained with H&E from 
single transgenic liFUT2 and h GLA, double trans­
genic hFUT2xhGLA, and non-transgenic pigs. The 
analysis showed no histological differences between 
the control and the transgenic samples.
Immunofluorescence staining
The localization o f recombinant human a. 1,2- 
fiicosyltransferase (rhal,2-FT) and a-galactosidase A 
(rha-Gal A) was examined by the immunofluores­
cence staining o f liver cryostat sections derived from 
single transgenic liFUT2 and h GLA, double trans­
genic hFUT2x\\GLA, and non-transgenic pigs. The 
positive immunofluorescence signal from rhal,2-FT 
was evenly distributed in the hepatic lobules o f the 
porcine liver derived from both transgenic lines 
hFUT2 and hFUT2xhGLA  (Fig. 2a and 2c). In turn, 
rha-Gal A immunostaining was less homogenous and 
detected in small clusters o f hepatocytes as well as in 
the interlobular space in the porcine liver o f transgenic 
variants hGLA and hFUT2xhGLA (Fig. 2b and 2d). In 
the control non-transgenic livers the rhal,2-FT  was 
barely detectable by immunofluorescence (Fig. 2e), 
while we did not observe any positive signal from re­
combinant human a-galactosidase (Fig. 2f). Double 
immunofluorescence labeling experiments demon­
strated colocalization o f the recombinant human 
al,2-fucosyltransferase with the Golgi resident 58K 
protein in the perinuclear region o f hepatocytes origi­
nated from both transgenic pig models, liFUT2 and 
\iFUT2xhGLA. Figure 4 shows representative mi­
crophotographs of immunofluorescence colocaliza­
tion of recombinant human-a.l,2 -fucosyltransferase 
(rhal,2-FT) and the Golgi apparatus (58K Golgi pro­
tein) in porcine liver cryostat sections derived from 
single (hFUT2) and double transgenic pigs 
(hFUT2xhGLA).
The semi-quantitative analysis o f fluorescence in­
tensity showed statistically significant, inter­
individual differences in the expression o f recombi­
nant human a l , 2 -fucosyltransferase between the con­
trol (CTR nTG) and both transgenic variants, \\FUT2 
(p<0.01) and hFUT2x\\GLA (p<0.001) (Fig. 3a). 
Moreover, significant differences were also detected 
between \iFUT2xhGLA and hFUT2 pigs (p<0.01). 
Considering recombinant human a-galactosidase ex­
pression, we did observe statistically significant 
differences between the control (CTR nTG) and both 
transgenic variants, h GLA (p<0.01) and 
hFUT2xhGLA (p<0.001), but there was no difference 
between the transgenic animals (Fig. 3b).
Western blot
Liver tissue samples were derived from single 
(hFUT2, hGLA) and double (hFUT2xhGLA) trans­
genic pigs as well as from non-transgenic, control 
pigs (CTRnTG). Western blot analysis of total protein 
extracts from porcine liver samples showed the pres­
ence o f recombinant human a l , 2 -fucosyltransferase 
and a-galactosiadase A proteins in all corresponding 
transgenic samples (Fig. 5a-c). In the control group 
(Fig. 5d), we observed a weak positive signal for 
rhal,2-FT and a barely detectable signal for human 
rha-Gal A. The signal intensities o f the analysed pro­
teins were normalized to beta-actin, which was used 
as a loading control. Quantitative analysis o f the 
Western blot showed that the relative expression of 
both tested proteins was significantly higher (at least 
p< 0 .0 1 ) in all transgenic variants than that in the con­
trol group (CTRnTG) (Fig. 5e and 5f). The specificity 
o f primary antibodies was detenu ined by the presence 
o f a single band in the liver samples, at the expected 
molecular weight, on a Western blot.
Lectin histochemistry
The expression profile of the G alal^3G al epitope 
was identified in porcine liver tissue sections by label­
ling with the specific lectin GS-IB 4  Alexa Fluor 647 
conjugated (Fig. 6 ). The lectin GS-IB4 strongly la­
belled Galal -3Gal in all the liver tissue sections of 
the control group (Fig. 6 a). In contrast, liver samples 
from the single transgenic pigs hFUT2, hGLA (Fig. 6 b 
and 6 c) and from the double transgenic pigs 
hFUT2xh.GLA (Fig. 6 d) displayed a much lower 
G alal ̂ 3Gal fluorescence intensity compared to the 
control group.
Semiquantitative analysis o f fluorescence intensity 
of the AlexaFluor 647 dye revealed that the 
Galal -3Gal epitope expression in the liver o f all 
three transgenic lines was significantly lower as com­
pared to the control non-transgenic pigs (Fig. 7) 
at p<0.01 for both hFUT2 and h GLA, and p<0.001 for 
hFUT2xhGLA. However, no significant differences 
were detected among the individual groups o f geneti­
cally modified animals (p>0.05).
Lectin blot analysis
Lectin blot analysis was used to detennine the ex­
pression profile o f Galal -3Gal at the total protein 
level using lectin GS-IB 4  labelled with HRP. The re­
sults showed the presence o f the Gahxl >3Gal epitope 
in all analysed porcine liver samples (Fig. 8 a). Beta­
actin served as a loading control. The quantitative 
analysis ofthe Galal -3Gal epitope showed statistical 
differences between the control group (CTR nTG) 
and all genetically modified liver samples (Fig. 8 b). 
The lowest significant expression o f the Galal >3 Gal 
epitope was observed in samples from double trans­
genic porcine livers (hFUT2xhGLA) and this was sta­
tistically different from both, hFUT2 (p<0.05) and 
h GLA (pcO.Ol) (Fig. 8 b). GALILI eta l. (1988) dem-
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Fig. 2. Immunofluorescence analysis of porcine liver cryostat tissue sections. Representative microphotographs of immunofluorescence 
localization of recombinant human: al,2-fucosyltransferase (rhul.2-FT) and a-galactosidase A (rha-Gal A) in porcine liver cryostat 
sections derived from single (a, b) and double transgenic pigs (c and d). Liver cryostat sections from non-transgenic pigs were used as 
a control group (CTR nTG) (e and f). Immimofluorescent staining with Cy3 labelled secondary antibodies (red) and DAPI 
counterstaining (blue). Scale bars = 100 pm. Immmioreaction was performed on liver serial sections from at least three pigs of each 
experimental group. The immunofluorescence signal from al,2-rhFT was distributed homogeneously in all lobules of porcine liver 
derived from each analysed transgenic variant (a and c). The recombinant human a-galactosidase A was located less homogeneously in 
smgle clusters of hepatocytes as well as in the interlobular space in the porcme liver of all variants (b and d). Analysis showed a barely 
detectable positive signal from rhal,2-FT (e) in the control group (CTR nTG). No positive signal from recombinant human 
a-galactosidase A in the control (CTR nTG) is seen (f).
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onstrated an abundance o f this epitope on mammalian 
cells including pig cells (1x106-30x106 epitopes/cell). 
Since in our study lectin blotting was performed on to­
tal protein samples, we postulate that the large 
number o f bands positive for Galal >3Gal result from 
a great quantity o f this epitope in pig liver cells.
Fig. 3. Relative expression of recombinant human: 
al,2-fucosyltransferase (a) and a-galactosidase A (b). For each 
genetically modified and control animal, three sections were 
sampled by 70 ROI. Data are presented as mean ± SEM and 
displayed as arbitrary units in exponential notation (x 103). 
One-way ANOVA and post hoc Tukey HSD test, values are 
denoted as **p<0.01, ***p<0.001.
Fig. 4. Immunofluorescent colocalisation of recombmant human 
al,2-fucosyltransferase and the Golgi apparatus in porcine liver 
cryostat tissue sections. Representative microphotographs of 
the immunofluorescence colocalization of recombinant human: 
al,2-fucosyltransferase (rhal,2-FT) and the Golgi apparatus 
(58K Golgi protein) in porcme liver cryostat sections derived 
from smgle (hFUT2) and double transgenic pigs 
(hFUT2x hGLA). Immunofluorescent staining with Alexa Fluor 
488 labelled secondary antibodies (green) for rhal,2-FT, Cy3 
labelled secondary antibodies (red) for the 58K Golgi protein, 
and DAPI counterstaining for nuclei (blue). Imrnimoreaction 
was performed on liver serial sections from at least three pigs 
from each experimental group. White arrows on the merged 
pictures show the colocalization of both analyzed proteins. 
Scale bars = 20 pm.
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Fig. 5. Western blot analysis of the relative expression of recombinant human: al,2-fucosyltransferase (rhal,2-FT) and a-galactosidase 
(rha-Gal A) proteins in transgenic and non-transgenic porcine livers. Representative blots of the expression of: rhal,2-FT and rha-Gal 
A proteins in the liver samples derived from smgle (a, b) and double transgenic (c) porcme livers. The liver samples of non-transgenic 
animals served as a control group (CTR nTG) -  panel d. The ß-actin was a loading control for all analyzed proteins. The results of the 
relative expression (ill arbitrary units) of: rhal,2-FT and rha-Gal A were shown in panels e andf, respectively. Bar graphs show mean 
±SEM of ROD from three separate analyses of three animals for each variant. The red line is taken as the cut-off value 1.0. Statistics: 
One-way ANOVA and post hoc Tukey HSD test, values are denoted as **p<0.01 and ***p<0.001.
Discussion
In this study we investigated the effects o f the over­
expression o f human a l , 2 -fucosyltransferase and 
a-galactosidase A on the amount o f Galal -3 Gal anti­
gen and hepatic histology in porcine liver from three 
transgenic lines. As genetically modified pigs were 
produced to avoid hyperacute rejection (LIPIŃSKI
et al. 2010; ZEYLAND et al. 2013, 2014), we discuss 
this aspect in relation to a liver model. Our immuno­
fluorescence and lectin blot analyses revealed a sig­
nificant reduction o f Galal -3Gal expression in the 
liver tissue in all three transgenic lines, hFUT2, 
h GLA, and hFUT2*hGLA, in comparison to non- 
transgenic pigs. More importantly, the double trans­
genic animals showed a significantly lower, but still
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Fig. 6. Lectin histochemistry analysis of the G alal-3G al epitope expression in porcme liver cryostat tissue sections. Representative 
microphotographs of lectin GS-IB4 labelled sections derived from: non-transgenic control (a), smgle transgenic (b and c), and double 
transgenic animals (d). The lectin histochemistry was performed with lectin GS-IB4 Alexa Fluor 647 conjugated (red) and DAPI 
counterstained (blue). Scale bars = 50 pm.
detectable, level o f the Galo. I *3Gal epitope than two 
other genetically modified pig lines, as was evidenced by 
lectin blotting. Collectively, our results indicate that 
the constitutive co-expression of cooperating enzymes 
such as recombinant human a l , 2 -fucosyltransferase 
and a-galactosidase A is more efficient in removing 
the Galal -3Gal antigen from porcine cells than the 
individual function o f either hFUT2 or hGLA. How­
ever, at present, we cannot exclude the possibility that 
the more effective removal o f the G alal -3Gal epi­
tope in the double transgenic line is also due to 
a higher level o f \xFUT2 expression when compared 
to the single transgenic liFUT2 line (see Fig. 3a).
Therefore, quantification o f transgene copy number 
and mRNA level o f \\FUT2 and hGLA in the liver 
should be carried out to verify this conclusion. Unfor­
tunately, incomplete removal o f the Galo.1 A Gal in 
double transgenic hFUT2xhGLA pigs indicates that 
this genetic modification alone is not to be considered 
for liver xenotransplantation. Hence, our data support 
emerging evidence that multi-transgenic pig models 
with a larger number o f deleted, humanized, or added 
genes are required for the effective elimination o f ma­
jor xenoantigen to prolong vascularised xenograft 
survival (Niem ann  & Petersen  2016). Undoubt­
edly, GTKO pigs represent the basis for further opti-
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Fig. 7. Semiquantitative analysis of fluorescence intensity of AlexaFluor 647 dye for the detection of G alal-3G al epitope expression. 
For each genetically modified and control animal, three sections were sampled by 70 ROI. Data are presented as mean ± SEM and 
displayed as arbitrary units in exponential notation (xlO3). Statistics: One-way ANOVA and post hoc Tukey F1SD test, values are 
denoted as **p<0.01 and ***p<0.001. A significantly lower relative expression of the Galal-3G al epitope in all tested samples 
compared to the control group (CTR nTG) is noted.
Fig. 8. Eastern blotting (lectm blotting) analysis of G alal-3G al epitope expression in transgenic and non-transgenic porcme liver 
samples at the protein level. Panel a: Representative lectm blots of the expression of the G alal-3G al epitope in liver samples derived 
from: non-transgenic (CTR nTG) control, single- (hFUT2, hGLA), and double transgenic (hFUT2xhGLA) pigs. MW indicates the 
molecular weight of protein standards. C l, C2, SI, S2 -  control 1, control 2, sample 1, sample 2, respectively. Each band represents 
a glycosylated protein containing the G alal-3G al epitope. The ß-actin served as a loading control for all analyzed samples. Panel b: 
The quantitative analysis of G alal-3G al epitope relative expression, data are presented as mean ± SEM from three separate ROD 
analyses of three animals for each variant, and displayed as arbitrary units in exponential notation (xlO3). One-way ANOVA and post 
hoc Tukey HSD test, values are denoted as: *p<0.05 and **p<0.01. Die relative expression of the G alal-3G al epitope was 
significantly lower in the liver of all transgenic pigs compared to the control (CTR nTG) non-transgenic animals. Within the transgenic 
animals, the lowest significant expression of the G alal-3G al epitope showed liver samples derived from double transgenic 
(hFUT2xhGLA) pigs. In other samples (hFUT2, hGLA) the expression remained at a similar level with no significant differences.
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mal genetic modifications. Recently, SHAH et al. 
(2017) established an orthotopic model o f GTKO 
pig-to-primate liver xenotransplantation with con­
tinuous human coagulation factor infusion and costimu­
lation blockade, in which baboon recipients survived 
up to 25 and 29 days while maintaining hepatic func­
tions. And this is the longest survival time of liver xe­
nografts to date. Moreover, two non-alpha Gal 
epitopes have been identified in pigs, namely /V-glyc- 
olylneuraminic acid (NeuSGc) and the SDa produced by 
the porcine ßl,4-N-acetylgalactosaminyltransferase-2 
(B4GALNT2), which may be a barrier to the clinical 
application o f xenotransplantation (BYRNE et al. 
2018; LADOWSKI et a l  2019; LU et a l  2020; TECTOR 
e ta l  2020). Hence, additional genome editing is cru­
cial to overcome the problems associated with im­
mune rejection.
The single transgenic pigs were obtained by micro­
injection o f linearized gene construct composed of 
human cytomegalovirus immediate early promoter 
and human al,2-fucosyltransferase or human a-gala- 
ctosidase coding sequences (LIPIŃSKI et al. 2010; 
ZEYLAND e ta l  2013). In turn, double transgenic pigs 
\\FUT2xhGLA were generated by interbreeding o f ap­
propriate single transgenic individuals (ZEYLAND et a l  
2014). Using PCR, Southern blot and flow cytometry 
LIPIŃSKI et al. (2010) and ZEYLAND et al. (2013, 
2014) confinned successful incorporation o f hFUT2 
and h GLA gene sequences in the porcine genome in 
skin fibroblasts derived from single transgenic and 
double transgenic pigs. Additionally, fluorescent in 
situ hybridization (FISH) analysis demonstrated that 
these gene sequences were located in specific regions 
o f the genome, 1\FUT2 on chromosome 14q28 and 
hGLA on chromosome 1 Ip 12. They also showed that 
both recombinant human a 1,2-fucosyltransferase and 
a-galactosiadase A may individually reduce the expres­
sion o f the Galal -3Gal epitope. Our finding that the 
single expression o f human a 1,2-fucosyltransferase 
may decrease the amount o f the Gala I *3Gal epitope 
in transgenic liver is consistent with earlier studies us­
ing different tissues (SANDRIN et al. 1995; SHARMA 
e ta l  1996; COSTA etal. 2008; LIPIŃSKI e ta l  2010). 
A previous study by JlA  et al. (2004) proved that 
a-galactosidase alone lowered epitope Galal >3Gal 
expression by 78%, while the co-expression o f 
a-galactosidase and a 1,2-fucosyltransferase reduced 
this epitope almost to zero on the surface o f SV40- 
immortalised aortic porcine endothelial cells. An­
other study by ZEYLAND et al. (2014) estimated the 
Galal -3Gal epitope reduction in porcine ear skin fi­
broblasts at 60% for a 1,2-fucosyltransferase, 58.9 % 
for a-galactosidase, and 66.9 %  for both a. 1,2- 
fucosyltransferase and a-galactosidase. Here we 
demonstrated by lectin histochemistry and lectin blot­
ting that Galal -3Gal epitope expression in porcine 
liver was decreased by 54% (histochemistry) and 
38% (blotting) in the \\FUT2 pigs. 59% and 35% in the 
Y\GLA animals, and finally by 62% and 47% in the
hl'UT2 y\\GLA pigs. Therefore, it is clear that the 
most effective approach to eliminating this epitope is 
generating homozygous GTKO pigs lacking the gene 
for al,3-galactosyltransferase.
We report here the abundant hepatic expression of 
recombinant human proteins al,2-fiicosyltransferase 
and a-galactosidase A in transgenic pigs, indicating 
an efficient and stable expression o f human transge­
nes in porcine livers. Our study also revealed the pre­
dominant, perinuclear localization o f human 
a 1,2-fucosyltransferase in porcine hepatocytes, as 
evidenced by the immunofluorescence analysis of 
porcine livers derived from single 1\FUT2 and double 
liFUT2 xhGLA transgenic animals. Moreover, double 
immunostaining with antibodies against human 
a. 1,2-fucosyltransferase and Golgi 58K protein pro­
vide evidence for the colocalization o f these two pro­
teins and support the view of a 1,2-fucosyltransferase 
distribution within the Golgi apparatus (MlLLAND 
et al. 2001). Indeed, in human cells a l,2 - 
fucosyltransferase is localized within the cis compart­
ment o f the Golgi complex, while in the porcine cells 
a.l,3-galactosyltransferase is present in the trans 
compartment (HARTEL-SCHENK et al. 1991). Hence, 
distinctive distribution o f these two enzymes in the 
Golgi network, which compete for the same substrate 
N-acetyllactosamine, allows for the lowering o f the 
G alal^3G al epitope in the porcine hepatocytes by 
rhal,2-FT.
Considering possible adverse effects o f the overex­
pression o f human transgenes on hepatic tissue integ­
rity and cell morphology, we performed a routine 
histological analysis o f the livers from the transgenic 
pigs. We found no histological evidence o f liver tissue 
abnormalities in the analyzed pigs, which may sug­
gest that these genetic modifications do not have dele­
terious effects on the functional morphology of 
porcine hepatic tissue.
In conclusion, we have shown that the overexpres­
sion o f recombinant human a 1,2-fucosyltransferase 
and a-galactosidase A in single and double transgenic 
pig models significantly reduces, but does not elimi­
nate the G alal >3Gal epitope from hepatic tissue. 
Hence, the efficacy o f this approach for liver modifi­
cation in xenotransplantation-related studies is lim­
ited as even hyperacute rejection remains a hurdle.
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